APAC markets are among the largest and fastest growing in the world, with a legacy of successful international collaborations within drug development and direct investment in biotechs. However, post-pandemic trade restrictions and new proposals, such as the BIOSECURE Act, indicate that future collaborations will require extra scrutiny, management, and clinical data expectations. This discussion will feature APAC-region experts exploring how best to mitigate risks while still pursuing projects to serve unmet needs of patients.​